Nonhuman primate studies have recently shown that Maxwell Biosciences has developed a breakthrough innovation to address humanity’s most serious, unmet infectious disease threats—one medicine for all pathogenic bacteria and fungi and biofilm formations. Maxwell's DARPA-seeded "Synthetic Immune System" technology is backed by over $63M in government grants and investor financing. The technology has scientific validation in over 500 peer-reviewed published studies and 7 US military Collaborative Research and Development Agreements. Maxwell received very encouraging Pre-IND feedback ahead of its FDA IND submission, anticipated in 2026. Maxwell's novel compounds are protected by a series of patents, and are likely to achieve Qualified Infectious Disease Product status which conveys Fast Track and 12 years of market exclusivity. Maxwell is creating a library of drug candidates designed to mimic natural immunity and extend health span—with $300+B in annual market potential within 10 years.